润都股份：硝酸异山梨酯化学原料药上市申请获批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Isosorbide Dinitrate, indicating a significant step in expanding its product portfolio in the cardiovascular treatment market [1] Group 1: Product Approval - The company announced the receipt of the approval notice for Isosorbide Dinitrate, a chemical raw material drug [1] - This product is indicated for the long-term treatment of coronary heart disease and prevention of angina pectoris [1] - It is also used for the treatment of persistent angina after myocardial infarction and in combination with digoxin and/or diuretics for chronic congestive heart failure [1] - Additionally, it is indicated for the treatment of pulmonary hypertension [1]